Skip to main content

Larson Tina Marriott's Form 4 filing

Recursion Pharmaceuticals, Inc. (RXRX) · filed Nov 17, 2023

Accession no.
0001209191-23-055846
Filed
Nov 17, 2023
Trade date
Nov 15-16, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $20.3K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Larson Tina MarriottCIK 0001856414Officer (President and COO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 15, 2023Class A Common StockFTax withholdingDisposed−5,378$7.18−$38,614.04413,404Direct
Nov 16, 2023Class A Common StockMOption exerciseAcquired+3,000$1.06+$3,180416,404Direct
Nov 16, 2023Class A Common StockSSaleDisposed−3,000$6.76−$20,280413,404Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 16, 2023Class A Common StockMOption exerciseDisposed−3,000$0.00$0520,000Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)